Real‑World Experience of 1 Year of Tralokinumab Treatment in Adult Patients with Atopic Dermatitis: A Single-Center Retrospective Study.

IF 3.5 3区医学 Q1 DERMATOLOGY

Dermatology and Therapy Pub Date : 2025-08-01 Epub Date: 2025-06-03 DOI:10.1007/s13555-025-01445-8

Adrian O Rodriguez, Caid Sterling Smith

{"title":"Real‑World Experience of 1 Year of Tralokinumab Treatment in Adult Patients with Atopic Dermatitis: A Single-Center Retrospective Study.","authors":"Adrian O Rodriguez, Caid Sterling Smith","doi":"10.1007/s13555-025-01445-8","DOIUrl":null,"url":null,"abstract":"Introduction: Atopic dermatitis (AD) is a chronic inflammatory disease requiring long-term management. Biologic therapies have emerged as systemic treatment options for AD, and real-world evidence (RWE) of their use is needed to inform optimal treatment decisions.Methods: A retrospective, single-center case series was conducted including 37 adults with AD who were systemic-naive or inadequately responded to previous AD treatment and had a visit around 1 year after tralokinumab initiation prior to May 2024. Patient demographics, disease characteristics, and treatment history were collected. Outcomes of tralokinumab treatment, including investigator's global assessment (IGA) score, body surface area (BSA), and adverse events (AEs), were extracted from a 2-month visit (defined as 1-3 months) and a 1-year visit (defined as ≥ 10 months) after tralokinumab initiation.Results: Thirty-seven patients (median age, 58.0 years; 49% male) on tralokinumab for approximately 1 year or longer were included. At baseline, most patients (97% [33/34]) had moderate-to-severe AD (IGA 3 or 4), and median (interquartile range [IQR]) BSA was 10.0% (5.0%; 18.8%); 19% (7/37) of patients were biologic-experienced, having been previously on dupilumab. Most patients (95% [35/37]) transitioned to tralokinumab due to inadequate response to previous treatment. The proportion of patients with IGA score 0 or 1 increased from 0% (0/34) at baseline to 85% (22/26) after 2 months and 93% (28/30) at 1 year of tralokinumab treatment. Median (IQR) BSA improved to 0.5% (0.0%; 1.0%) and 0.0% (0.0%; 1.0%) at the 2-month and 1-year visits, respectively. Similar improvements were observed regardless of Fitzpatrick skin type or previous treatment history. No AEs were reported through 1 year of follow-up.Conclusions: This large case series provides RWE building on tralokinumab clinical trial data and highlights the potential rapid and long-term response in patients with AD irrespective of their Fitzpatrick skin type or treatment history, including patients previously treated with dupilumab.","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2307-2315"},"PeriodicalIF":3.5000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256368/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01445-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Atopic dermatitis (AD) is a chronic inflammatory disease requiring long-term management. Biologic therapies have emerged as systemic treatment options for AD, and real-world evidence (RWE) of their use is needed to inform optimal treatment decisions.

Methods: A retrospective, single-center case series was conducted including 37 adults with AD who were systemic-naive or inadequately responded to previous AD treatment and had a visit around 1 year after tralokinumab initiation prior to May 2024. Patient demographics, disease characteristics, and treatment history were collected. Outcomes of tralokinumab treatment, including investigator's global assessment (IGA) score, body surface area (BSA), and adverse events (AEs), were extracted from a 2-month visit (defined as 1-3 months) and a 1-year visit (defined as ≥ 10 months) after tralokinumab initiation.

Results: Thirty-seven patients (median age, 58.0 years; 49% male) on tralokinumab for approximately 1 year or longer were included. At baseline, most patients (97% [33/34]) had moderate-to-severe AD (IGA 3 or 4), and median (interquartile range [IQR]) BSA was 10.0% (5.0%; 18.8%); 19% (7/37) of patients were biologic-experienced, having been previously on dupilumab. Most patients (95% [35/37]) transitioned to tralokinumab due to inadequate response to previous treatment. The proportion of patients with IGA score 0 or 1 increased from 0% (0/34) at baseline to 85% (22/26) after 2 months and 93% (28/30) at 1 year of tralokinumab treatment. Median (IQR) BSA improved to 0.5% (0.0%; 1.0%) and 0.0% (0.0%; 1.0%) at the 2-month and 1-year visits, respectively. Similar improvements were observed regardless of Fitzpatrick skin type or previous treatment history. No AEs were reported through 1 year of follow-up.

Conclusions: This large case series provides RWE building on tralokinumab clinical trial data and highlights the potential rapid and long-term response in patients with AD irrespective of their Fitzpatrick skin type or treatment history, including patients previously treated with dupilumab.

查看原文本刊更多论文

成人特应性皮炎患者1年曲洛单抗治疗的真实世界经验：一项单中心回顾性研究

特应性皮炎（AD）是一种需要长期治疗的慢性炎症性疾病。生物疗法已成为阿尔茨海默病的系统治疗选择，需要其使用的真实证据（RWE）来为最佳治疗决策提供信息。方法：一项回顾性的单中心病例系列研究包括37名成人AD患者，他们对以前的AD治疗没有充分的反应，并在曲罗单抗开始治疗1年后（2024年5月之前）就诊。收集患者人口统计资料、疾病特征和治疗史。曲洛单抗治疗的结果，包括研究者总体评估（IGA）评分、体表面积（BSA）和不良事件（ae），从曲洛单抗开始治疗后2个月（定义为1-3个月）和1年（定义为≥10个月）的随访中提取。结果：37例患者(中位年龄58.0岁；（49%男性）接受曲洛单抗治疗约1年或更长时间。在基线时，大多数患者（97%[33/34]）患有中重度AD (IGA 3或4)，中位（四分位间距[IQR]） BSA为10.0% (5.0%；18.8%);19%（7/37）的患者曾接受过dupilumab的生物学治疗。大多数患者（95%[35/37]）由于对先前治疗的反应不足而过渡到曲洛单抗。IGA评分为0或1的患者比例从基线时的0%（0/34）增加到2个月后的85%（22/26）和曲洛单抗治疗1年后的93%（28/30）。中位（IQR） BSA改善至0.5% (0.0%；1.0%)和0.0% (0.0%；1.0%)，分别于2个月及1年访视。无论菲茨帕特里克皮肤类型或既往治疗史如何，均观察到类似的改善。随访1年无不良事件发生。结论：这一大型病例系列为RWE提供了曲匹单抗临床试验数据，并强调了AD患者的潜在快速和长期反应，无论其Fitzpatrick皮肤类型或治疗史如何，包括先前接受过杜匹单抗治疗的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology and Therapy Medicine-Dermatology

CiteScore

6.00

自引率

8.80%

发文量

187

审稿时长

6 weeks

期刊介绍： Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.